|
1. Chan WK, Dan YY, Wong VW; GO ASIA Initiative. Editorial: NAFLD in Asia-clinical associations with advanced disease become clearer. Authors' reply. Aliment Pharmacol Ther. 2018 Apr; 47(7): 1037-38. doi: 10.1111/apt.14572 2. Bălănescu A, Bălănescu P, Comănici V, Stan I, Acs B, Prisăcariu L, et al. Lipid profile pattern in pediatric overweight population with or without NAFLD in relation to IDF criteria for metabolic syndrome: a preliminary study. Rom J Intern Med. 2018 Mar; 56(1): 47-54. doi: 10.1515/rjim-2017-0040 3. Chaudhury CS, Purdy JB, Liu CY, Morse CG, Stanley TL, Kleiner D, et al. Unanticipated increases in hepatic steatosis among human immunodeficiency virus patients receiving mineralocorticoid receptor antagonist eplerenone for non-alcoholic fatty liver disease. Liver Int. 2018 May; 38(5): 797-802. doi: 10.1111/liv.13734 4. Pollack M, Phaneuf S, Dirks A, Leeuwenburgh C. The role of apoptosis in the normal aging brain, skeletal muscle, and heart. Ann N Y Acad Sci. 2002 Apr; 959: 93-107. doi: 10.1111/j.1749-6632.2002.tb02086.x 5. Seya K, Kanemaru K, Sugimoto C, Suzuki M, Takeo T, Motomura S, et al. Opposite effects of two resveratrol (trans-3,5,4'-trihydroxystilbene) tetramers, vitisin A and hopeaphenol, on apoptosis of myocytes isolated from adult rat heart. J Pharmacol Exp Ther. 2009 Jan; 328(1): 90-8. doi: 10.1124/jpet.108.143172 6. Wang CC, Lin SK, Tseng YF, Hsu CS, Tseng TC, Lin HH, et al. Elevation of serum aminotransferase activity increases risk of carotid atherosclerosis in patients with non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 2009 Aug; 24(8): 1411-16. doi: 10.1111/j.1440-1746.2009.05872.x 7. Shaikh AH, Aatif S, Ahmed T. Carotid Intima-Media Thickness in Patients with Non-Alcoholic Fatty Liver Disease. J Basic Appl Sci. 2013; 9: 333-36. 8. Vlachopoulos C, Manesis E, Baou K, Papatheodoridis G, Koskinas J, Tiniakos D, et al. Increased arterial stiffness and impaired endothelial function in nonalcoholic Fatty liver disease: a pilot study. Am J Hypertens. 2010 Nov; 23(11): 1183-89. doi: 10.1038/ajh.2010.144 9. Caserta CA, Pendino GM, Amante A, Vacalebre C, Fiorillo MT, Surace P, et al. Cardiovascular risk factors, nonalcoholic fatty liver disease, and carotid artery intima-media thickness in an adolescent population in southern Italy. Am J Epidemiol. 2010 Jun; 171(11): 1195-202. doi: 10.1093/aje/kwq073 10. Khan RS, Newsome PN. NAFLD in 2017: Novel insights into mechanisms of disease progression. Nat Rev Gastroenterol Hepatol. 2018 Feb; 15(2): 71-72. doi: 10.1038/nrgastro.2017.181 11. Rietman A, Sluik D, Feskens EJM, Kok FJ, Mensink M. Associations between dietary factors and markers of NAFLD in a general Dutch adult population. Eur J Clin Nutr. 2018 Jan; 72(1): 117-23. doi: 10.1038/ejcn.2017.148 12. Zhang Z, Wang J, Wang H. Correlation of blood glucose, serum chemerin and insulin resistance with NAFLD in patients with type 2 diabetes mellitus. Exp Ther Med. 2018 Mar; 15(3): 2936-40. doi: 10.3892/etm.2018.5753 13. Wu B, Ma Y, Yi Z, Liu S, Rao S, Zou L, et al. Resveratrol-decreased hyperalgesia mediated by the P2X7 receptor in gp120-treated rats. Mol Pain. 2017 Jan-Dec; 13: 1744806917707667. doi: 10.1177/1744806917707667 14. Hajighasem A, Farzanegi P, Mazaheri Z. Effects of combined therapy with resveratrol, continuous and interval exercises on apoptosis, oxidative stress, and inflammatory biomarkers in the liver of old rats with non-alcoholic fatty liver disease. Arch Physiol Biochem. 2019 May; 125(2): 142-49. doi: 10.1080/13813455.2018.1441872 15. Efati M, Khorrami M, Zarei Mahmmodabadi A, Raouf Sarshoori J. [Induction of an Animal Model of Non-Alcoholic Fatty Liver Disease Using a Formulated High-Fat Diet]. J Babol Univ Med Sci. 2016; 18(11): 57-62. doi: 10.22088/jbums.18.11.57 [Article in Persian] 16. Batacan RB Jr, Duncan MJ, Dalbo VJ, Connolly KJ, Fenning AS. Light-intensity and high-intensity interval training improve cardiometabolic health in rats. Appl Physiol Nutr Metab. 2016 Sep; 41(9): 945-52. doi: 10.1139/apnm-2016-0037 17. Freitas DA, Rocha-Vieira E, Soares BA, Nonato LF, Fonseca SR, Martins JB, et al. High intensity interval training modulates hippocampal oxidative stress, BDNF and inflammatory mediators in rats. Physiol Behav. 2018 Feb; 184: 6-11. doi: 10.1016/j.physbeh.2017.10.027 18. Fealy CE, Haus JM, Solomon TP, Pagadala M, Flask CA, McCullough AJ, et al. Short-term exercise reduces markers of hepatocyte apoptosis in nonalcoholic fatty liver disease. J Appl Physiol (1985). 2012 Jul; 113(1): 1-6. doi: 10.1152/japplphysiol.00127.2012 19. Thong-Ngam D, Samuhasaneeto S, Kulaputana O, Klaikeaw N. N-acetylcysteine attenuates oxidative stress and liver pathology in rats with non-alcoholic steatohepatitis. World J Gastroenterol. 2007 Oct; 13(38): 5127-32. 20. Ding C, Zhao Y, Shi X, Zhang N, Zu G, Li Z, et al. New insights into salvianolic acid A action: Regulation of the TXNIP/NLRP3 and TXNIP/ChREBP pathways ameliorates HFD-induced NAFLD in rats. Sci Rep. 2016; 6: 28734. doi: 10.1038/srep28734 21. Kumar A, Sharma A, Duseja A, Das A, Dhiman RK, Chawla YK, et al. Patients with Nonalcoholic Fatty Liver Disease (NAFLD) have Higher Oxidative Stress in Comparison to Chronic Viral Hepatitis. J Clin Exp Hepatol. 2013 Mar; 3(1): 12-18. doi: 10.1016/j.jceh.2012.10.009 22. El-Din SH, Sabra AN, Hammam OA, Ebeid FA, El-Lakkany NM. Pharmacological and antioxidant actions of garlic and.or onion in non-alcoholic fatty liver disease (NAFLD) in rats. J Egypt Soc Parasitol. 2014 Aug; 44(2): 295-308. 23. Wang H, Jiang T, Li W, Gao N, Zhang T. Resveratrol attenuates oxidative damage through activating mitophagy in an in vitro model of Alzheimer's disease. Toxicol Lett. 2018 Jan; 282: 100-108. doi: 10.1016/j.toxlet.2017.10.021 24. Tung BT, Rodríguez-Bies E, Ballesteros-Simarro M, Motilva V, Navas P, López-Lluch G. Modulation of endogenous antioxidant activity by resveratrol and exercise in mouse liver is age dependent. J Gerontol A Biol Sci Med Sci. 2014 Apr; 69(4): 398-409. doi: 10.1093/gerona/glt102
|
